Skip to content

Treating Opioid Misuse Via Mindfulness-Based Just-in-Time Adaptive Intervention

Reating Opioid Misuse Via Mindfulness-Based Just-in-Time Adaptive Intervention

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04567043
Acronym
MORE-JITAI
Enrollment
63
Registered
2020-09-28
Start date
2020-09-24
Completion date
2023-09-30
Last updated
2023-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain

Brief summary

This pilot RCT will examine the preliminary efficacy of a telehealth version of Mindfulness-Oriented Recovery Enhancement (MORE) enriched with a smartphone-based just-in-time adaptive intervention (JITAI) for patients with chronic pain on long-term opioid therapy.

Interventions

BEHAVIORALMORE+JITAI

Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse. JITAI involves stress-triggered reminders to practice mindfulness skills.

BEHAVIORALSupporive Psychotherapy

A supportive psychotherapy group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.

Sponsors

University of Utah
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Current chronic pain diagnosis determined by physician assessment (including but not limited to ICD-9 diagnoses 338.0, 338.21, 338.22, 338.28, 338.29, 338.4) * Current use of prescription opioid agonist or mixed agonist-antagonist analgesics for \>90 days * Willingness to participate in study interventions and assessments

Exclusion criteria

* Prior experience with Mindfulness-Based Stress Reduction, Mindfulness-Based Cognitive Therapy, or Mindfulness-Based Relapse Prevention * Active suicidality, schizophrenia, psychotic disorder * Presence of clinically unstable systemic illness judged to interfere with treatment * No access to internet (which will prevent telehealth-based treatment)

Design outcomes

Primary

MeasureTime frameDescription
Change in momentary cravingBaseline through 1-month follow-upCraving measured by numeric rating scale via ecological momentary assessments (min 0, max 10, with higher scores meaning more craving)
Change in momentary pain: numeric rating scaleBaseline through 1-month follow-upPain measured by numeric rating scale via ecological momentary assessments (min 0, max 10, with higher scores meaning more pain)

Secondary

MeasureTime frameDescription
Change in momentary positive affectBaseline through 1-month follow-upPositive affect measured by numeric rating scale via ecological momentary assessments (min 0, max 10, with higher scores meaning more positive affect)
Change in momentary stressBaseline through 1-month follow-upStress measured by numeric rating scale via ecological momentary assessments (min 0, max 10, with higher scores meaning more stress)
Change in heart rate variabilityBaseline through 1-month follow-upChanges in heart rate variability (HRV) measured via ambulatory HRV assessment

Other

MeasureTime frameDescription
Change in opioid misuseBaseline through post-treatment (week 8)Scores on Current Opioid Misuse Measure, with higher scores indicating higher opioid misuse (min 0, max 68)
Change in opioid doseBaseline through post-treatment (week 8)Opioid dose as assessed with Timeline Followback Procedure
Change in chronic pain symptomsBaseline through post-treatment (week 8)Scores on Brief Pain Inventory, with higher scores indicating higher pain severity (min 0, max 10)
Change in self-transcendenceBaseline through post-treatment (week 8)Self-transcendence measured by Nondual Awareness Dimensional Assessment, with higher scores indicating higher self-transcendence (min 13, max 65)
Change in mindful reinterpretation of pain sensationsBaseline through post-treatment (week 8)Mindful reinterpretation of pain sensations measured by the Mindful Reinterpretation of Pain Sensations Scale, with higher scores indicating higher reinterpretation of pain sensations (min 0, max 45)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026